Global Daptomycin
Global Daptomycin

Daptomycin Comprehensive Study by Type (350 mg lyophilized powder, 500 mg lyophilized powder), Application (Adult, Pediatric patients (1 to 17 years of age)) Players and Region - Global Market Outlook to 2024

Daptomycin Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 201 Pages 187 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Daptomycin Market Study:
Merck & Co.(United States), Pfizer (United States), Teva (Israel), Mylan (United States), Fresenius Kabi (Germany), Sagent Pharmaceuticals (United States), Xellia (Denmark), HENGRUI PHARMA (China) and Huadong Medicine (China)

In the last few years, Global market of Daptomycin developed rapidly. Major factors driving the market are Increasing Complicated Skin & Skin Structure Infections .

On the basis of product type, the Daptomycin market is segmented by 350 mg lyophilized powder and 500 mg lyophilized powder.

On the basis of applications, the Daptomycin market is segmented by Adult and Pediatric patients (1 to 17 years of age).

Recent Industry Highlights:
.

. The Global Daptomycin market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Daptomycin market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Daptomycin market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Daptomycin Manufactures, Daptomycin Distributors, Pharmaceutical Companies, Private Research Organizations and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • 350 mg lyophilized powder
  • 500 mg lyophilized powder
By Application
  • Adult
  • Pediatric patients (1 to 17 years of age)
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Complicated Skin & Skin Structure Infections
      • 3.2.2. Prevalence of many Diseases that are caused by Bacteria
    • 3.3. Market Challenges
      • 3.3.1. High Cost of these Drugs
      • 3.3.2. Issue Related Towards the Side Effects of Daptomycin such as constipation (6%), nausea (6%), and headache (5%)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Daptomycin, by Type, Application and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Daptomycin (Value)
      • 5.2.1. Global Daptomycin by: Type (Value)
        • 5.2.1.1. 350 mg lyophilized powder
        • 5.2.1.2. 500 mg lyophilized powder
      • 5.2.2. Global Daptomycin by: Application (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Pediatric patients (1 to 17 years of age)
      • 5.2.3. Global Daptomycin Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Daptomycin (Volume)
      • 5.3.1. Global Daptomycin by: Type (Volume)
        • 5.3.1.1. 350 mg lyophilized powder
        • 5.3.1.2. 500 mg lyophilized powder
      • 5.3.2. Global Daptomycin by: Application (Volume)
        • 5.3.2.1. Adult
        • 5.3.2.2. Pediatric patients (1 to 17 years of age)
      • 5.3.3. Global Daptomycin Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Daptomycin (Price)
      • 5.4.1. Global Daptomycin by: Type (Price)
  • 6. Daptomycin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co.(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fresenius Kabi (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sagent Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Xellia (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. HENGRUI PHARMA (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Huadong Medicine (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Daptomycin Sale, by Type, Application and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Daptomycin (Value)
      • 7.2.1. Global Daptomycin by: Type (Value)
        • 7.2.1.1. 350 mg lyophilized powder
        • 7.2.1.2. 500 mg lyophilized powder
      • 7.2.2. Global Daptomycin by: Application (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Pediatric patients (1 to 17 years of age)
      • 7.2.3. Global Daptomycin Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Daptomycin (Volume)
      • 7.3.1. Global Daptomycin by: Type (Volume)
        • 7.3.1.1. 350 mg lyophilized powder
        • 7.3.1.2. 500 mg lyophilized powder
      • 7.3.2. Global Daptomycin by: Application (Volume)
        • 7.3.2.1. Adult
        • 7.3.2.2. Pediatric patients (1 to 17 years of age)
      • 7.3.3. Global Daptomycin Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Daptomycin (Price)
      • 7.4.1. Global Daptomycin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Daptomycin: by Type(USD Million)
  • Table 2. Daptomycin 350 mg lyophilized powder , by Region USD Million (2013-2018)
  • Table 3. Daptomycin 500 mg lyophilized powder , by Region USD Million (2013-2018)
  • Table 4. Daptomycin: by Application(USD Million)
  • Table 5. Daptomycin Adult , by Region USD Million (2013-2018)
  • Table 6. Daptomycin Pediatric patients (1 to 17 years of age) , by Region USD Million (2013-2018)
  • Table 7. South America Daptomycin, by Country USD Million (2013-2018)
  • Table 8. South America Daptomycin, by Type USD Million (2013-2018)
  • Table 9. South America Daptomycin, by Application USD Million (2013-2018)
  • Table 10. Brazil Daptomycin, by Type USD Million (2013-2018)
  • Table 11. Brazil Daptomycin, by Application USD Million (2013-2018)
  • Table 12. Argentina Daptomycin, by Type USD Million (2013-2018)
  • Table 13. Argentina Daptomycin, by Application USD Million (2013-2018)
  • Table 14. Rest of South America Daptomycin, by Type USD Million (2013-2018)
  • Table 15. Rest of South America Daptomycin, by Application USD Million (2013-2018)
  • Table 16. Asia Pacific Daptomycin, by Country USD Million (2013-2018)
  • Table 17. Asia Pacific Daptomycin, by Type USD Million (2013-2018)
  • Table 18. Asia Pacific Daptomycin, by Application USD Million (2013-2018)
  • Table 19. China Daptomycin, by Type USD Million (2013-2018)
  • Table 20. China Daptomycin, by Application USD Million (2013-2018)
  • Table 21. Japan Daptomycin, by Type USD Million (2013-2018)
  • Table 22. Japan Daptomycin, by Application USD Million (2013-2018)
  • Table 23. India Daptomycin, by Type USD Million (2013-2018)
  • Table 24. India Daptomycin, by Application USD Million (2013-2018)
  • Table 25. South Korea Daptomycin, by Type USD Million (2013-2018)
  • Table 26. South Korea Daptomycin, by Application USD Million (2013-2018)
  • Table 27. Taiwan Daptomycin, by Type USD Million (2013-2018)
  • Table 28. Taiwan Daptomycin, by Application USD Million (2013-2018)
  • Table 29. Australia Daptomycin, by Type USD Million (2013-2018)
  • Table 30. Australia Daptomycin, by Application USD Million (2013-2018)
  • Table 31. Rest of Asia-Pacific Daptomycin, by Type USD Million (2013-2018)
  • Table 32. Rest of Asia-Pacific Daptomycin, by Application USD Million (2013-2018)
  • Table 33. Europe Daptomycin, by Country USD Million (2013-2018)
  • Table 34. Europe Daptomycin, by Type USD Million (2013-2018)
  • Table 35. Europe Daptomycin, by Application USD Million (2013-2018)
  • Table 36. Germany Daptomycin, by Type USD Million (2013-2018)
  • Table 37. Germany Daptomycin, by Application USD Million (2013-2018)
  • Table 38. France Daptomycin, by Type USD Million (2013-2018)
  • Table 39. France Daptomycin, by Application USD Million (2013-2018)
  • Table 40. Italy Daptomycin, by Type USD Million (2013-2018)
  • Table 41. Italy Daptomycin, by Application USD Million (2013-2018)
  • Table 42. United Kingdom Daptomycin, by Type USD Million (2013-2018)
  • Table 43. United Kingdom Daptomycin, by Application USD Million (2013-2018)
  • Table 44. Netherlands Daptomycin, by Type USD Million (2013-2018)
  • Table 45. Netherlands Daptomycin, by Application USD Million (2013-2018)
  • Table 46. Rest of Europe Daptomycin, by Type USD Million (2013-2018)
  • Table 47. Rest of Europe Daptomycin, by Application USD Million (2013-2018)
  • Table 48. MEA Daptomycin, by Country USD Million (2013-2018)
  • Table 49. MEA Daptomycin, by Type USD Million (2013-2018)
  • Table 50. MEA Daptomycin, by Application USD Million (2013-2018)
  • Table 51. Middle East Daptomycin, by Type USD Million (2013-2018)
  • Table 52. Middle East Daptomycin, by Application USD Million (2013-2018)
  • Table 53. Africa Daptomycin, by Type USD Million (2013-2018)
  • Table 54. Africa Daptomycin, by Application USD Million (2013-2018)
  • Table 55. North America Daptomycin, by Country USD Million (2013-2018)
  • Table 56. North America Daptomycin, by Type USD Million (2013-2018)
  • Table 57. North America Daptomycin, by Application USD Million (2013-2018)
  • Table 58. United States Daptomycin, by Type USD Million (2013-2018)
  • Table 59. United States Daptomycin, by Application USD Million (2013-2018)
  • Table 60. Canada Daptomycin, by Type USD Million (2013-2018)
  • Table 61. Canada Daptomycin, by Application USD Million (2013-2018)
  • Table 62. Mexico Daptomycin, by Type USD Million (2013-2018)
  • Table 63. Mexico Daptomycin, by Application USD Million (2013-2018)
  • Table 64. Daptomycin Sales: by Type(Units)
  • Table 65. Daptomycin Sales 350 mg lyophilized powder , by Region Units (2013-2018)
  • Table 66. Daptomycin Sales 500 mg lyophilized powder , by Region Units (2013-2018)
  • Table 67. Daptomycin Sales: by Application(Units)
  • Table 68. Daptomycin Sales Adult , by Region Units (2013-2018)
  • Table 69. Daptomycin Sales Pediatric patients (1 to 17 years of age) , by Region Units (2013-2018)
  • Table 70. South America Daptomycin Sales, by Country Units (2013-2018)
  • Table 71. South America Daptomycin Sales, by Type Units (2013-2018)
  • Table 72. South America Daptomycin Sales, by Application Units (2013-2018)
  • Table 73. Brazil Daptomycin Sales, by Type Units (2013-2018)
  • Table 74. Brazil Daptomycin Sales, by Application Units (2013-2018)
  • Table 75. Argentina Daptomycin Sales, by Type Units (2013-2018)
  • Table 76. Argentina Daptomycin Sales, by Application Units (2013-2018)
  • Table 77. Rest of South America Daptomycin Sales, by Type Units (2013-2018)
  • Table 78. Rest of South America Daptomycin Sales, by Application Units (2013-2018)
  • Table 79. Asia Pacific Daptomycin Sales, by Country Units (2013-2018)
  • Table 80. Asia Pacific Daptomycin Sales, by Type Units (2013-2018)
  • Table 81. Asia Pacific Daptomycin Sales, by Application Units (2013-2018)
  • Table 82. China Daptomycin Sales, by Type Units (2013-2018)
  • Table 83. China Daptomycin Sales, by Application Units (2013-2018)
  • Table 84. Japan Daptomycin Sales, by Type Units (2013-2018)
  • Table 85. Japan Daptomycin Sales, by Application Units (2013-2018)
  • Table 86. India Daptomycin Sales, by Type Units (2013-2018)
  • Table 87. India Daptomycin Sales, by Application Units (2013-2018)
  • Table 88. South Korea Daptomycin Sales, by Type Units (2013-2018)
  • Table 89. South Korea Daptomycin Sales, by Application Units (2013-2018)
  • Table 90. Taiwan Daptomycin Sales, by Type Units (2013-2018)
  • Table 91. Taiwan Daptomycin Sales, by Application Units (2013-2018)
  • Table 92. Australia Daptomycin Sales, by Type Units (2013-2018)
  • Table 93. Australia Daptomycin Sales, by Application Units (2013-2018)
  • Table 94. Rest of Asia-Pacific Daptomycin Sales, by Type Units (2013-2018)
  • Table 95. Rest of Asia-Pacific Daptomycin Sales, by Application Units (2013-2018)
  • Table 96. Europe Daptomycin Sales, by Country Units (2013-2018)
  • Table 97. Europe Daptomycin Sales, by Type Units (2013-2018)
  • Table 98. Europe Daptomycin Sales, by Application Units (2013-2018)
  • Table 99. Germany Daptomycin Sales, by Type Units (2013-2018)
  • Table 100. Germany Daptomycin Sales, by Application Units (2013-2018)
  • Table 101. France Daptomycin Sales, by Type Units (2013-2018)
  • Table 102. France Daptomycin Sales, by Application Units (2013-2018)
  • Table 103. Italy Daptomycin Sales, by Type Units (2013-2018)
  • Table 104. Italy Daptomycin Sales, by Application Units (2013-2018)
  • Table 105. United Kingdom Daptomycin Sales, by Type Units (2013-2018)
  • Table 106. United Kingdom Daptomycin Sales, by Application Units (2013-2018)
  • Table 107. Netherlands Daptomycin Sales, by Type Units (2013-2018)
  • Table 108. Netherlands Daptomycin Sales, by Application Units (2013-2018)
  • Table 109. Rest of Europe Daptomycin Sales, by Type Units (2013-2018)
  • Table 110. Rest of Europe Daptomycin Sales, by Application Units (2013-2018)
  • Table 111. MEA Daptomycin Sales, by Country Units (2013-2018)
  • Table 112. MEA Daptomycin Sales, by Type Units (2013-2018)
  • Table 113. MEA Daptomycin Sales, by Application Units (2013-2018)
  • Table 114. Middle East Daptomycin Sales, by Type Units (2013-2018)
  • Table 115. Middle East Daptomycin Sales, by Application Units (2013-2018)
  • Table 116. Africa Daptomycin Sales, by Type Units (2013-2018)
  • Table 117. Africa Daptomycin Sales, by Application Units (2013-2018)
  • Table 118. North America Daptomycin Sales, by Country Units (2013-2018)
  • Table 119. North America Daptomycin Sales, by Type Units (2013-2018)
  • Table 120. North America Daptomycin Sales, by Application Units (2013-2018)
  • Table 121. United States Daptomycin Sales, by Type Units (2013-2018)
  • Table 122. United States Daptomycin Sales, by Application Units (2013-2018)
  • Table 123. Canada Daptomycin Sales, by Type Units (2013-2018)
  • Table 124. Canada Daptomycin Sales, by Application Units (2013-2018)
  • Table 125. Mexico Daptomycin Sales, by Type Units (2013-2018)
  • Table 126. Mexico Daptomycin Sales, by Application Units (2013-2018)
  • Table 127. Daptomycin: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Daptomycin: by Type(USD Million)
  • Table 138. Daptomycin 350 mg lyophilized powder , by Region USD Million (2019-2024)
  • Table 139. Daptomycin 500 mg lyophilized powder , by Region USD Million (2019-2024)
  • Table 140. Daptomycin: by Application(USD Million)
  • Table 141. Daptomycin Adult , by Region USD Million (2019-2024)
  • Table 142. Daptomycin Pediatric patients (1 to 17 years of age) , by Region USD Million (2019-2024)
  • Table 143. South America Daptomycin, by Country USD Million (2019-2024)
  • Table 144. South America Daptomycin, by Type USD Million (2019-2024)
  • Table 145. South America Daptomycin, by Application USD Million (2019-2024)
  • Table 146. Brazil Daptomycin, by Type USD Million (2019-2024)
  • Table 147. Brazil Daptomycin, by Application USD Million (2019-2024)
  • Table 148. Argentina Daptomycin, by Type USD Million (2019-2024)
  • Table 149. Argentina Daptomycin, by Application USD Million (2019-2024)
  • Table 150. Rest of South America Daptomycin, by Type USD Million (2019-2024)
  • Table 151. Rest of South America Daptomycin, by Application USD Million (2019-2024)
  • Table 152. Asia Pacific Daptomycin, by Country USD Million (2019-2024)
  • Table 153. Asia Pacific Daptomycin, by Type USD Million (2019-2024)
  • Table 154. Asia Pacific Daptomycin, by Application USD Million (2019-2024)
  • Table 155. China Daptomycin, by Type USD Million (2019-2024)
  • Table 156. China Daptomycin, by Application USD Million (2019-2024)
  • Table 157. Japan Daptomycin, by Type USD Million (2019-2024)
  • Table 158. Japan Daptomycin, by Application USD Million (2019-2024)
  • Table 159. India Daptomycin, by Type USD Million (2019-2024)
  • Table 160. India Daptomycin, by Application USD Million (2019-2024)
  • Table 161. South Korea Daptomycin, by Type USD Million (2019-2024)
  • Table 162. South Korea Daptomycin, by Application USD Million (2019-2024)
  • Table 163. Taiwan Daptomycin, by Type USD Million (2019-2024)
  • Table 164. Taiwan Daptomycin, by Application USD Million (2019-2024)
  • Table 165. Australia Daptomycin, by Type USD Million (2019-2024)
  • Table 166. Australia Daptomycin, by Application USD Million (2019-2024)
  • Table 167. Rest of Asia-Pacific Daptomycin, by Type USD Million (2019-2024)
  • Table 168. Rest of Asia-Pacific Daptomycin, by Application USD Million (2019-2024)
  • Table 169. Europe Daptomycin, by Country USD Million (2019-2024)
  • Table 170. Europe Daptomycin, by Type USD Million (2019-2024)
  • Table 171. Europe Daptomycin, by Application USD Million (2019-2024)
  • Table 172. Germany Daptomycin, by Type USD Million (2019-2024)
  • Table 173. Germany Daptomycin, by Application USD Million (2019-2024)
  • Table 174. France Daptomycin, by Type USD Million (2019-2024)
  • Table 175. France Daptomycin, by Application USD Million (2019-2024)
  • Table 176. Italy Daptomycin, by Type USD Million (2019-2024)
  • Table 177. Italy Daptomycin, by Application USD Million (2019-2024)
  • Table 178. United Kingdom Daptomycin, by Type USD Million (2019-2024)
  • Table 179. United Kingdom Daptomycin, by Application USD Million (2019-2024)
  • Table 180. Netherlands Daptomycin, by Type USD Million (2019-2024)
  • Table 181. Netherlands Daptomycin, by Application USD Million (2019-2024)
  • Table 182. Rest of Europe Daptomycin, by Type USD Million (2019-2024)
  • Table 183. Rest of Europe Daptomycin, by Application USD Million (2019-2024)
  • Table 184. MEA Daptomycin, by Country USD Million (2019-2024)
  • Table 185. MEA Daptomycin, by Type USD Million (2019-2024)
  • Table 186. MEA Daptomycin, by Application USD Million (2019-2024)
  • Table 187. Middle East Daptomycin, by Type USD Million (2019-2024)
  • Table 188. Middle East Daptomycin, by Application USD Million (2019-2024)
  • Table 189. Africa Daptomycin, by Type USD Million (2019-2024)
  • Table 190. Africa Daptomycin, by Application USD Million (2019-2024)
  • Table 191. North America Daptomycin, by Country USD Million (2019-2024)
  • Table 192. North America Daptomycin, by Type USD Million (2019-2024)
  • Table 193. North America Daptomycin, by Application USD Million (2019-2024)
  • Table 194. United States Daptomycin, by Type USD Million (2019-2024)
  • Table 195. United States Daptomycin, by Application USD Million (2019-2024)
  • Table 196. Canada Daptomycin, by Type USD Million (2019-2024)
  • Table 197. Canada Daptomycin, by Application USD Million (2019-2024)
  • Table 198. Mexico Daptomycin, by Type USD Million (2019-2024)
  • Table 199. Mexico Daptomycin, by Application USD Million (2019-2024)
  • Table 200. Daptomycin Sales: by Type(Units)
  • Table 201. Daptomycin Sales 350 mg lyophilized powder , by Region Units (2019-2024)
  • Table 202. Daptomycin Sales 500 mg lyophilized powder , by Region Units (2019-2024)
  • Table 203. Daptomycin Sales: by Application(Units)
  • Table 204. Daptomycin Sales Adult , by Region Units (2019-2024)
  • Table 205. Daptomycin Sales Pediatric patients (1 to 17 years of age) , by Region Units (2019-2024)
  • Table 206. South America Daptomycin Sales, by Country Units (2019-2024)
  • Table 207. South America Daptomycin Sales, by Type Units (2019-2024)
  • Table 208. South America Daptomycin Sales, by Application Units (2019-2024)
  • Table 209. Brazil Daptomycin Sales, by Type Units (2019-2024)
  • Table 210. Brazil Daptomycin Sales, by Application Units (2019-2024)
  • Table 211. Argentina Daptomycin Sales, by Type Units (2019-2024)
  • Table 212. Argentina Daptomycin Sales, by Application Units (2019-2024)
  • Table 213. Rest of South America Daptomycin Sales, by Type Units (2019-2024)
  • Table 214. Rest of South America Daptomycin Sales, by Application Units (2019-2024)
  • Table 215. Asia Pacific Daptomycin Sales, by Country Units (2019-2024)
  • Table 216. Asia Pacific Daptomycin Sales, by Type Units (2019-2024)
  • Table 217. Asia Pacific Daptomycin Sales, by Application Units (2019-2024)
  • Table 218. China Daptomycin Sales, by Type Units (2019-2024)
  • Table 219. China Daptomycin Sales, by Application Units (2019-2024)
  • Table 220. Japan Daptomycin Sales, by Type Units (2019-2024)
  • Table 221. Japan Daptomycin Sales, by Application Units (2019-2024)
  • Table 222. India Daptomycin Sales, by Type Units (2019-2024)
  • Table 223. India Daptomycin Sales, by Application Units (2019-2024)
  • Table 224. South Korea Daptomycin Sales, by Type Units (2019-2024)
  • Table 225. South Korea Daptomycin Sales, by Application Units (2019-2024)
  • Table 226. Taiwan Daptomycin Sales, by Type Units (2019-2024)
  • Table 227. Taiwan Daptomycin Sales, by Application Units (2019-2024)
  • Table 228. Australia Daptomycin Sales, by Type Units (2019-2024)
  • Table 229. Australia Daptomycin Sales, by Application Units (2019-2024)
  • Table 230. Rest of Asia-Pacific Daptomycin Sales, by Type Units (2019-2024)
  • Table 231. Rest of Asia-Pacific Daptomycin Sales, by Application Units (2019-2024)
  • Table 232. Europe Daptomycin Sales, by Country Units (2019-2024)
  • Table 233. Europe Daptomycin Sales, by Type Units (2019-2024)
  • Table 234. Europe Daptomycin Sales, by Application Units (2019-2024)
  • Table 235. Germany Daptomycin Sales, by Type Units (2019-2024)
  • Table 236. Germany Daptomycin Sales, by Application Units (2019-2024)
  • Table 237. France Daptomycin Sales, by Type Units (2019-2024)
  • Table 238. France Daptomycin Sales, by Application Units (2019-2024)
  • Table 239. Italy Daptomycin Sales, by Type Units (2019-2024)
  • Table 240. Italy Daptomycin Sales, by Application Units (2019-2024)
  • Table 241. United Kingdom Daptomycin Sales, by Type Units (2019-2024)
  • Table 242. United Kingdom Daptomycin Sales, by Application Units (2019-2024)
  • Table 243. Netherlands Daptomycin Sales, by Type Units (2019-2024)
  • Table 244. Netherlands Daptomycin Sales, by Application Units (2019-2024)
  • Table 245. Rest of Europe Daptomycin Sales, by Type Units (2019-2024)
  • Table 246. Rest of Europe Daptomycin Sales, by Application Units (2019-2024)
  • Table 247. MEA Daptomycin Sales, by Country Units (2019-2024)
  • Table 248. MEA Daptomycin Sales, by Type Units (2019-2024)
  • Table 249. MEA Daptomycin Sales, by Application Units (2019-2024)
  • Table 250. Middle East Daptomycin Sales, by Type Units (2019-2024)
  • Table 251. Middle East Daptomycin Sales, by Application Units (2019-2024)
  • Table 252. Africa Daptomycin Sales, by Type Units (2019-2024)
  • Table 253. Africa Daptomycin Sales, by Application Units (2019-2024)
  • Table 254. North America Daptomycin Sales, by Country Units (2019-2024)
  • Table 255. North America Daptomycin Sales, by Type Units (2019-2024)
  • Table 256. North America Daptomycin Sales, by Application Units (2019-2024)
  • Table 257. United States Daptomycin Sales, by Type Units (2019-2024)
  • Table 258. United States Daptomycin Sales, by Application Units (2019-2024)
  • Table 259. Canada Daptomycin Sales, by Type Units (2019-2024)
  • Table 260. Canada Daptomycin Sales, by Application Units (2019-2024)
  • Table 261. Mexico Daptomycin Sales, by Type Units (2019-2024)
  • Table 262. Mexico Daptomycin Sales, by Application Units (2019-2024)
  • Table 263. Daptomycin: by Type(USD/Units)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Daptomycin: by Type USD Million (2013-2018)
  • Figure 5. Global Daptomycin: by Application USD Million (2013-2018)
  • Figure 6. South America Daptomycin Share (%), by Country
  • Figure 7. Asia Pacific Daptomycin Share (%), by Country
  • Figure 8. Europe Daptomycin Share (%), by Country
  • Figure 9. MEA Daptomycin Share (%), by Country
  • Figure 10. North America Daptomycin Share (%), by Country
  • Figure 11. Global Daptomycin: by Type Units (2013-2018)
  • Figure 12. Global Daptomycin: by Application Units (2013-2018)
  • Figure 13. South America Daptomycin Share (%), by Country
  • Figure 14. Asia Pacific Daptomycin Share (%), by Country
  • Figure 15. Europe Daptomycin Share (%), by Country
  • Figure 16. MEA Daptomycin Share (%), by Country
  • Figure 17. North America Daptomycin Share (%), by Country
  • Figure 18. Global Daptomycin: by Type USD/Units (2013-2018)
  • Figure 19. Global Daptomycin share by Players 2018 (%)
  • Figure 20. Global Daptomycin share by Players (Top 3) 2018(%)
  • Figure 21. Global Daptomycin share by Players (Top 5) 2018(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Merck & Co.(United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co.(United States) Revenue: by Geography 2018
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2018
  • Figure 27. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva (Israel) Revenue: by Geography 2018
  • Figure 29. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan (United States) Revenue: by Geography 2018
  • Figure 31. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Fresenius Kabi (Germany) Revenue: by Geography 2018
  • Figure 33. Sagent Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Sagent Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 35. Xellia (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. Xellia (Denmark) Revenue: by Geography 2018
  • Figure 37. HENGRUI PHARMA (China) Revenue, Net Income and Gross profit
  • Figure 38. HENGRUI PHARMA (China) Revenue: by Geography 2018
  • Figure 39. Huadong Medicine (China) Revenue, Net Income and Gross profit
  • Figure 40. Huadong Medicine (China) Revenue: by Geography 2018
  • Figure 41. Global Daptomycin: by Type USD Million (2019-2024)
  • Figure 42. Global Daptomycin: by Application USD Million (2019-2024)
  • Figure 43. South America Daptomycin Share (%), by Country
  • Figure 44. Asia Pacific Daptomycin Share (%), by Country
  • Figure 45. Europe Daptomycin Share (%), by Country
  • Figure 46. MEA Daptomycin Share (%), by Country
  • Figure 47. North America Daptomycin Share (%), by Country
  • Figure 48. Global Daptomycin: by Type Units (2019-2024)
  • Figure 49. Global Daptomycin: by Application Units (2019-2024)
  • Figure 50. South America Daptomycin Share (%), by Country
  • Figure 51. Asia Pacific Daptomycin Share (%), by Country
  • Figure 52. Europe Daptomycin Share (%), by Country
  • Figure 53. MEA Daptomycin Share (%), by Country
  • Figure 54. North America Daptomycin Share (%), by Country
  • Figure 55. Global Daptomycin: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Merck & Co.(United States)
  • Pfizer (United States)
  • Teva (Israel)
  • Mylan (United States)
  • Fresenius Kabi (Germany)
  • Sagent Pharmaceuticals (United States)
  • Xellia (Denmark)
  • HENGRUI PHARMA (China)
  • Huadong Medicine (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation